Cingulate Inc. (CING) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Kansas City, KS, アメリカ. 現CEOは Shane J. Schaffer.
CING を有する IPO日 2021-12-08, 13 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $29.15M.
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
